Guardion Health Sciences Product Licensee Receives Registration Approval in Malaysia for Immune Support Supplement
August 27 2020 - 8:30AM
Guardion Health Sciences, Inc. (“Guardion” or the “Company”)
(Nasdaq: GHSI) today announced that Ho Wah Genting Berhad (“HWGB”),
a Malaysian company listed on the Malaysian Stock Exchange
(KLSE:9601), has received product registration approval for
Astramern Nutra V, an immune support dietary supplement designed
and produced by Guardion. The approval of Astramern Nutra V by the
Malaysian National Pharmaceutical Regulatory Agency (“NPRA”), which
is effective through August 21, 2025, represents an important step
in HWGB’s efforts to market and distribute Astramern Nutra V in
Malaysia.
In early 2020, HWGB entered into a Manufacturing
and Supply Agreement with Guardion for Guardion to design and
manufacture two immune support dietary supplements, Astramern Nutra
V, a vitamin formulation, and Astramern Nutra H, an herb
formulation. HWGB’s healthcare subsidiary, Astramern Sdn Bhd, has
an exclusive license to use and distribute these products in
certain territories. The two products will be packaged together for
sale by HWGB in Malaysia. Product registration approval of
Astramern Nutra H is pending with the NPRA. Guardion fulfilled
HWGB’s initial product order of $890,000 in June 2020.
Astramern Nutra V is provided in capsule form
and includes several important vitamins known to support the immune
system and healthy bodily function, most notably
N-acetyl-L-cysteine, which helps to replenish cellular glutathione,
one of the body’s most potent antioxidants.
Dr. David Evans, Ph.D., Guardion’s interim
President and Chief Executive Officer, commented, “We are pleased
that Ho Wah Genting Berhad has obtained product registration
approval for Astramern Nutra V. Immune support dietary supplements
represent a rapidly growing sector of the nutraceutical industry,
and we believe that our expertise in developing and delivering
unique immune support products in this sector will be a key
component of future revenue growth in the United States and
abroad.”
About Guardion Health Sciences,
Inc.
Guardion is a specialty health sciences company
(i) that develops medical foods and medical devices in the ocular
health marketplace and (ii) that is developing nutraceuticals that
the Company believes will provide medicinal and health benefits to
consumers. Information and risk factors with respect to Guardion
and its business, including its ability to successfully develop and
commercialize its proprietary products and technologies, may be
obtained in the Company’s filings with the SEC at www.sec.gov.
About Ho Wah Genting Berhad
Ho Wah Genting Berhad (“HWGB”) is principally
engaged in investment holdings and providing management services to
its subsidiaries. On June 30, 2020, HWGB, through its subsidiaries,
had diversified its existing businesses to include the healthcare
industry, including health supplements, biotechnology and health
technology. HWGB and its subsidiaries are also engaged in
investment holdings; manufacturing of wires and cables and molded
power supply cord sets and cable assemblies for electrical and
electronic devices and equipment; trading of wires and cables; and
travel agent and tour-related services.
Forward-Looking Statement
Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Statements
preceded by, followed by or that otherwise include the words
“believes,” “expects,” “anticipates,” “intends,” “projects,”
“estimates,” “plans” and similar expressions or future or
conditional verbs such as “will,” “should,” “would,” “may” and
“could” are generally forward- looking in nature and not historical
facts, although not all forward-looking statements include the
foregoing. These statements involve unknown risks and
uncertainties that may individually or materially impact the
matters discussed herein for a variety of reasons that are outside
the control of the Company, including, but not limited to, the
Company’s ability to raise sufficient financing to implement its
business plan, the impact of the COVID-19 pandemic on the Company’s
business, operations and the economy in general, and the Company’s
ability to successfully develop and commercialize its proprietary
products and technologies. Readers are cautioned not to place
undue reliance on these forward- looking statements, as actual
results could differ materially from those described in the
forward-looking statements contained herein. Readers are
urged to read the risk factors set forth in the Company’s filings
with the SEC, which are available at the SEC’s website
(www.sec.gov). The Company disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Investor Relations Contact: MKR
Investor Relations, Inc.Todd KehrliE-mail:
ghsi@mkr-group.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Sep 2023 to Sep 2024